Genentech's leukemia drug obinutuzumab shows promise in trial

02/1/2013 | American City Business Journals · OncLive

Treatment-naive patients with chronic lymphocytic leukemia who took Genentech's experimental drug GA-101, or obinutuzumab, in combination with chlorambucil, survived significantly longer without their disease worsening compared with patients who took chlorambucil alone, a late-stage trial found. Genentech plans to submit this trial's data to U.S. and European regulators for potential approval.

View Full Article in:

American City Business Journals · OncLive

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations